Fatima Tuz Zahra, MD, a hematology/oncology fellow at Moffitt Cancer Center, University of South Florida, Tampa, presented real-world data from a retrospective study evaluating the effectiveness of oral azacitidine as maintenance therapy in acute myeloid leukemia (AML) patients who achieved complete remission. The study reported a median relapse-free survival of 17.9 months and a median overall survival that was not yet reached, with 6- and 12-month overall survival rates of 93.3% and 84.8%, respectively. These findings align with results from the QUAZAR AML-001 trial, supporting oral azacitidine as a viable maintenance option for patients with AML not eligible for stem cell transplantation.